DiaSorin and Cytek Biosciences, Inc. announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging business unit.

On February 6, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and China Resources Pharmaceutical Commercial Group Co., Ltd. held a signing ceremony in the headquarter of Mindray in Shenzhen.

Recently, Sysmex and Shanghai Pinnacles Medical Technology Co., Ltd. reached a strategic cooperation.

January-December 2022 results rose significantly, with net profit attributable to shareholders of the listed company amounting to CNY 1,720 million to 1,880 million, representing a year-on-year net profit growth of 101.84% to 120.62%.

Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the fourth quarter and fiscal year 2022, which include consolidated financial results for GRAIL.

A-share listed Sinocare issued a full-year performance forecast. The Company expects a significant rise in January-December 2022 results, net profit attributable to shareholders of the listed company is CNY 400 million to 460 million, net profit increased by 271.85% to 327.63% year-on-year.

Qiagen reported on Tuesday that its fourth quarter sales declined 14 percent with an expected decrease in COVID-related sales offset by increased sales in the firm's non-COVID portfolio.

Assure Tech released a full-year earnings forecast, in which the company expects its January-December 2022 results to rise sharply, with net profit attributable to shareholders of the listed company amounting to CNY 2.895 to 3.378 billion, a net profit increase of 292.06% to 357.40% year-on-year.

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2022.

BGI Genomics released the 2022 annual fiscal forecast. The operating revenue is expected to reach CNY 6.4 to 7.4 billion; the net profit attributable to shareholders of the listed companies is forecast to be CNY 800 million to 1.04 billion.